Comparative Pharmacology
Head-to-head clinical analysis: ESKALITH CR versus LITHANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESKALITH CR versus LITHANE.
ESKALITH CR vs LITHANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lithium modulates neurotransmitter activity, inhibits inositol monophosphatase, affects G-protein signaling, and alters gene expression for neuroprotective effects.
Lithium is thought to modulate neurotransmitter release and second messenger systems, including inhibition of inositol monophosphatase and alterations in G-protein signaling, though exact mechanism in bipolar disorder is unclear.
Lithium carbonate extended-release (Eskalith CR) is administered orally. Typical adult starting dose: 300 mg 2-3 times daily. Maintenance dose: 900-1200 mg/day in 2-3 divided doses. Dose adjustments guided by serum lithium levels (target 0.6-1.2 mEq/L). Maximum dose: 2400 mg/day.
300-600 mg orally 3 times daily; usual therapeutic serum lithium level 0.6-1.2 mEq/L. Extended-release formulations given 2-3 times daily.
None Documented
None Documented
Terminal half-life: 18–24 hours (single dose); 24–36 hours (steady state). Extended due to slow tissue redistribution and age-related decreased GFR.
18-24 hours (single dose); 24-36 hours after chronic dosing; prolonged in elderly or renal impairment.
Renal: >95% unchanged. Biliary/fecal: negligible (<1%).
Renal: >95% unchanged; tubular reabsorption parallels sodium; negligible biliary/fecal.
Category C
Category C
Mood Stabilizer
Mood Stabilizer